Traci McCarty Marni Kottle
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y
Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges
Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio
PDUFA Action Date of May 30, 2027 for VOXZOGO ® for the Treatment of Hypochondroplasia (HCH)
Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., November 2, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026.
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “We are building on this achievement by continuing to expand our pipeline through focused business development. We are excited to add our newest asset, an investigational treatment for Fabry disease, which has the potential to become the first subcutaneous enzyme therapy for this condition. With this fourth new asset added to our pipeline in 2026, we are following through on our commitment to build sustainable growth for the future.” Mr. Hardy added, “As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.” 1
• BioMarin is accelerating innovation by expanding its pipeline through business development. Four transactions in 2026 have added development programs from preclinical through Phase 3:
◦ BMN 450 (HM15421/GC1134A) is an investigational long-acting enzyme replacement therapy (ERT) that has the potential to be the first subcutaneous ERT for Fabry disease. Now in a global Phase 1/2 clinical study, it could extend BioMarin’s reach beyond patients with genetic variants amenable to GALAFOLD ® .
◦ BMN 440 (ALE1) for hypophosphatasia (HPP) is a potential first-in-class oral therapy for HPP. The Phase 1/2a study in healthy volunteers and adults with HPP is ongoing, with data expected in 2027.
◦ BMN 430 for ReNU syndrome has the potential to be a first-in-disease antisense oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare neurodevelopmental condition with no approved targeted therapies. Preclinical studies are underway to identify a lead ASO candidate.
◦ BMN 820 (DMX-200) for focal segmental glomerulosclerosis (FSGS) is a first-in- class oral CCR2 inhibitor for which BioMarin holds exclusive U.S. commercialization rights. The Phase 3 ACTION 3 trial is fully enrolled, with pivotal data expected in 2028.
• Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 30, 2027 for its supplemental NDA to expand the use of VOXZOGO for the treatment of HCH, the first potential targeted therapy for the condition. BioMarin also announced today that the European Medicines Agency (EMA) validated its submission for the approval of VOXZOGO to treat HCH.
• BioMarin’s application for full approval of VOXZOGO in children with achondroplasia is under review by the FDA, with a PDUFA target action date of February 28, 2027. The application includes long-term safety and efficacy data, such as final adult height and clinical outcomes beyond linear growth.
• The Phase 2/3 study for BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia, continues to enroll on track. Dose-response data from this study is expected in 2027.
• In October, five-year results from the PROPEL open-label extension study with POMBILITI ® + OPFOLDA ® were presented in a late-breaking presentation at the World Muscle Society Annual Congress. In adults with late-onset Pompe disease, POMBILITI + OPFOLDA demonstrated durable motor function outcomes and relative stabilization of pulmonary function. This included people who had received enzyme replacement therapy for a mean of 7.6 years before enrolling. No new safety signals were identified.
• For BMN 351, BioMarin’s Phase 1/2 candidate for Duchenne muscular dystrophy, the company expects to provide a program update by year-end.
• In the first full quarter as part of BioMarin, GALAFOLD and POMBILITI + OPFOLDA delivered strong quarterly revenue, contributing $152 million and $49 million, respectively. The number of patients treated with GALAFOLD and POMBILITI + OPFOLDA increased by approximately 13% and 69% Y/Y, respectively. POMBILITI + OPFOLDA uptake benefited from supply constraints for other Pompe therapies.
• Metabolic Conditions revenue grew 44% Y/Y in the third quarter of 2026 and 26% Y/Y year-to-date. Growth was driven by the additions of GALAFOLD and POMBILITI + OPFOLDA and by higher VIMIZIM ® revenue. The number of patients on therapy increased across all BioMarin-marketed Metabolic Conditions therapies, Y/Y.
• VOXZOGO revenue grew 12% Y/Y in the third quarter of 2026, and the number of children treated with VOXZOGO globally increased 17% Y/Y. As of the end of the quarter, children with achondroplasia in 58 countries around the world were being treated with VOXZOGO. More than 75% of VOXZOGO revenue was generated outside of the U.S., and a large international order previously expected in the third quarter is now anticipated in the fourth quarter. In the U.S., the majority of new patient starts were in children under the age of two. 2
• BioMarin continued to integrate Amicus in the third quarter, realizing accelerated cost synergies to enable investments in initiatives to drive future growth of GALAFOLD and POMBILITI + OPFOLDA. BioMarin continues to expect approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) to be fully realized in 2028.
• On August 30, 2026, the company announced the global settlement of all outstanding claims with Ascendis Pharma A/S related to its product Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.
for the third quarter of 2026 were $1,025 million, an increase of 32% compared to the same period in 2025, primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired on April 27, 2026, as well as 18% revenue growth in VIMIZIM due to timing of large international orders. In the quarter, VOXZOGO revenue also increased by 12% due to new patients initiating therapy. These increases were partially offset by a decrease in NAGLAZYME ® revenue due to timing of large international orders.
increased to $123 million compared to $31 million for the same period in 2025. The increase was primarily driven by the acquisition of Amicus Therapeutics (Amicus), including intangible asset amortization, interest expense from debt issued to finance a portion of the transaction, amortization of inventory fair value step-up, and integration and restructuring costs. The increase was also attributed to acquired in-process research and development (IPR&D) charges recorded in the quarter in connection with the acquisition of Alesta Therapeutics (Alesta). These increases were partially offset by revenue growth as described above.
for the third quarter of 2026 increased to $45 million compared to $22 million for the same period in 2025. The increase was primarily driven by revenue growth, partially offset by higher acquired IPR&D charges and higher interest expense, as described above. The increases were also partially offset by higher sales and marketing spend related to GALAFOLD and POMBILITI + OPFOLDA. 3
Financial Highlights (in millions of U.S. dollars, except percentages and per share data, unaudited)
NM Percentage change is not meaningful for products acquired from Amicus on April 27, 2026.
(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non- GAAP Diluted EPS along with the related reconciliations to the comparable information reported under U.S. GAAP.
(3) GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations divided by Total Revenues. 4
BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors.
• Revenue: Total Revenues, Metabolic Conditions, and VOXZOGO guidance updated to reflect uncertainty in the timing of multiple orders from a single international customer.
• Non-GAAP Diluted EPS: BioMarin expects the Alesta acquisition and BMN 450 license agreement to result in total pre-tax charges of approximately $320 million and $83 million, respectively, for the full year 2026, consisting of the acquired IPR&D charges and ongoing operating expenses, representing an unfavorable impact of approximately $1.55 and $0.32, respectively, to both GAAP Diluted EPS and Non-GAAP Diluted EPS for the full year 2026.
(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS.
(3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted- Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss third quarter 2026 financial results today, Monday, November 2, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com.
U.S./Canada Dial-in Number:+1 Replay Dial-in Number: +1 833-309-1852 833-461-5787 International Dial-in Number: +1 Replay International Dial-in Number: +44 626-884-3620 800 007 4044 Conference ID: 324 588 583 Conference ID: 324 588 583
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 5
This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Revenues and Non- GAAP Diluted EPS for, in certain instances, the full-year 2026 and fourth quarter of 2026, and future periods, and the underlying drivers of those results, such as the expected demand and continued growth of BioMarin’s Metabolic Conditions portfolio, including PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA, and VOXZOGO, and the expected impact of the acquisition of Alesta Therapeutics B.V. (Alesta) and the BMN 450 license agreement; the anticipated benefits of the acquisition of Amicus Therapeutics, Inc., including the expected amount and timing of cost synergies as well as expected revenue from the addition of GALAFOLD and POMBILITI + OPFOLDA; the anticipated benefits of the acquisition of Alesta; the anticipated benefits of the BMN 450 license agreement; the anticipated benefits of the global settlement with Ascendis Pharma A/S, including BioMarin’s expected receipt of royalty payments on net sales of Yuviwel in the United States, the European Union, Brazil and South Korea; BioMarin’s plans for investment in innovation and future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of BioMarin’s product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of BioMarin’s commercial products and product candidates, including with respect to the potential new indication for VOXZOGO in hypochondroplasia; and potential growth opportunities and trends, including the assumptions and expectations regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin’s product candidates and commercial products.
These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin’s success in the commercialization of its commercial products; BioMarin’s ability to successfully integrate and realize the anticipated benefits of any acquisitions and license agreements; BioMarin’s ability to accurately estimate future financial performance; impacts of macroeconomic and other external factors on BioMarin’s operations, regulatory uncertainty, the impact of new or increased tariffs, other trade protection measures, and escalating trade tensions; geopolitical instability, wars and military conflicts; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; BioMarin’s ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; BioMarin’s ability to meet product demand; actual sales of BioMarin’s commercial products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin ® , VOXZOGO ® , VIMIZIM ® , NAGLAZYME ® , PALYNZIQ ® , BRINEURA ® , KUVAN ® , ROCTAVIAN ® , GALAFOLD ® , and POMBILITI ® + OPFOLDA ® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME ® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners. 6
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Unaudited ASSETS Current assets: Cash and cash $ 736,007 $ 1,311,679 equivalents Short-term — 248,930 investments Accounts receivable, 1,076,355 908,214 net Inventory 1,796,069 1,298,883 Other current 312,205 185,784 assets Total current 3,920,636 3,953,490 assets Noncurrent assets: Long-term — 492,242 investments Property, plant and 980,081 952,508 equipment, net Intangible 4,777,247 213,837 assets, net Goodwill 666,367 196,199 Deferred tax 897,787 1,508,697 assets Other assets 327,113 277,049 Total assets $ 11,569,231 $ 7,594,022 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and $ 946,107 $ 759,031 accrued liabilities Current portion of 658,717 — long-term debt, net Total current 1,604,824 759,031 liabilities Noncurrent liabilities: Long-term 3,514,974 597,176 debt, net Other long-term 193,401 150,816 liabilities Total 5,313,199 1,507,023 liabilities Stockholders’ equity: Common stock, $0.001 par value: 500,000,000 shares authorized; 193,676,831 194 192 and 192,300,101 shares issued and outstanding, respectively Additional paid-in 6,089,036 5,956,582 capital Company common stock held by the Nonqualified -10,851 -10,508 Deferred Compensation Plan Accumulated other -4,011 -13,473 comprehensive loss Retained 181,664 154,206 earnings Total stockholders’ 6,256,032 6,086,999 equity Total liabilities and $ 11,569,231 $ 7,594,022 stockholders’ equity
CASH FLOWS FROM Nine Months Ended OPERATING September 30, ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 27,458 $ 395,474 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 244,514 59,119 amortization Non-cash interest 30,548 1,969 expense Stock-based 172,684 134,496 compensation Impairment of assets 15,203 2,967 Acquired IPR&D 282,258 220,963 expense Deferred income -27,490 48,125 taxes Unrealized foreign exchange losses -8,380 244 (gains) Other -7,091 -5,399 Changes in operating assets and liabilities, net of effects of business acquired:
Accounts receivable, -60,435 -107,378 net Inventory -1,621 -98,796 Other current assets -54,369 -32,125 Other assets 12,859 -32,679 Accounts payable and -52,675 119,478 accrued liabilities Other long-term 3,511 21,892 liabilities Net cash provided by operating 576,974 728,350 activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and -78,032 -62,316 equipment Maturities and sales 767,277 294,547 of investments Purchases of -25,792 -313,262 investments Business combination, net of -5,067,630 — cash acquired Purchases of IPR&D, -277,881 -285,193 net of cash acquired Other investing -1,191 -5,569 activities, net Net cash used in -4,683,249 -371,793 investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercises of awards under 6,655 7,714 equity incentive plans Taxes paid related to net share -43,330 -53,265 settlement of equity awards Proceeds from 3,650,000 — borrowings Payments of debt -65,605 — issuance costs Repayments of -15,000 — borrowings Net cash provided by (used in) financing 3,532,720 -45,551 activities Effect of exchange -2,117 -3,740 rate changes on cash NET INCREASE (DECREASE) IN CASH -575,672 307,266 AND CASH EQUIVALENTS Cash and cash equivalents: Beginning of period $ 1,311,679 $ 942,842 End of period $ 736,007 $ 1,250,108
The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non- GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company’s equity plans or convertible debt in periods when they are dilutive under Non-GAAP. Non-GAAP synergies is defined by the company as Amicus’ legacy labor and external spend cost reductions, excluding the impact of stock-based compensation.
BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure. Because these Non-GAAP metrics are important internal measurements for BioMarin, the company believes that providing this information in conjunction with BioMarin’s GAAP information enhances investors’ and analysts’ ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s principal business.
Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information: 10
(2) Stock-based compensation expense recorded in SG&A for the nine months ended September 30, 2026, includes approximately $13 million related to the post- combination service period for unvested Amicus stock options.
(3) Represents amortization of the inventory step-up for the inventory acquired in the Amicus transaction.
(4) The 2026 amounts represent severance, transaction and integration costs resulting from the Amicus acquisition, as well as restructuring costs incurred in connection with corporate initiatives. The 2025 amounts represent severance costs incurred in connection with the acquisition of Inozyme Pharma, Inc.
(5) Represents impairment loss on non-marketable equity securities recorded in Other income, net, in the first quarter of 2025.
(6) Common stock issuable under the company’s equity plans and convertible debt were excluded from the computation of GAAP and Non-GAAP Weighted-Average Diluted Shares Outstanding in the periods they were anti-dilutive. 12
Full text with the tables
Exhibit 99.1
Contact:
Investors: Media:
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803
BioMarin Reports Third Quarter 2026 Financial and Operating Results
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth
Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal
Conditions Y/Y
Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact
of Two Acquired In-process Research and Development (IPR&D) Charges
Recently Announced the Addition of a New Investigational Fabry Asset to Clinical
Portfolio
PDUFA Action Date of May 30, 2027 for VOXZOGO ® for the Treatment of
Hypochondroplasia (HCH)
Conference Call and Webcast Scheduled Today at 4:30 p.m. ET
SAN RAFAEL, Calif., November 2, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ:
BMRN) today announced financial results for the third quarter ended September
30, 2026.
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a
more diversified portfolio following the acquisition of Amicus Therapeutics
earlier this year and increased demand for our medicines from patients around
the world. For the first time, quarterly revenue exceeded $1 billion, a
milestone for BioMarin,” said Alexander Hardy, President and Chief Executive
Officer of BioMarin. “We are building on this achievement by continuing to
expand our pipeline through focused business development. We are excited to add
our newest asset, an investigational treatment for Fabry disease, which has the
potential to become the first subcutaneous enzyme therapy for this condition.
With this fourth new asset added to our pipeline in 2026, we are following
through on our commitment to build sustainable growth for the future.” Mr. Hardy
added, “As we approach 2027, we are well positioned for our next chapter of
growth, including the potential launch of VOXZOGO in hypochondroplasia and the
continued execution of our financial and innovation strategy.”
1
2026 Business and Pipeline Highlights
Innovation
• BioMarin is accelerating innovation by expanding its pipeline through business
development. Four transactions in 2026 have added development programs from
preclinical through Phase 3:
◦ BMN 450 (HM15421/GC1134A) is an investigational long-acting enzyme replacement
therapy (ERT) that has the potential to be the first subcutaneous ERT for Fabry
disease. Now in a global Phase 1/2 clinical study, it could extend BioMarin’s
reach beyond patients with genetic variants amenable to GALAFOLD ® .
◦ BMN 440 (ALE1) for hypophosphatasia (HPP) is a potential first-in-class oral
therapy for HPP. The Phase 1/2a study in healthy volunteers and adults with HPP
is ongoing, with data expected in 2027.
◦ BMN 430 for ReNU syndrome has the potential to be a first-in-disease antisense
oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare
neurodevelopmental condition with no approved targeted therapies. Preclinical
studies are underway to identify a lead ASO candidate.
◦ BMN 820 (DMX-200) for focal segmental glomerulosclerosis (FSGS) is a first-in-
class oral CCR2 inhibitor for which BioMarin holds exclusive U.S.
commercialization rights. The Phase 3 ACTION 3 trial is fully enrolled, with
pivotal data expected in 2028.
• Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has
set a PDUFA target action date of May 30, 2027 for its supplemental NDA to
expand the use of VOXZOGO for the treatment of HCH, the first potential targeted
therapy for the condition. BioMarin also announced today that the European
Medicines Agency (EMA) validated its submission for the approval of VOXZOGO to
treat HCH.
• BioMarin’s application for full approval of VOXZOGO in children with
achondroplasia is under review by the FDA, with a PDUFA target action date of
February 28, 2027. The application includes long-term safety and efficacy data,
such as final adult height and clinical outcomes beyond linear growth.
• The Phase 2/3 study for BMN 333, BioMarin's long-acting C-type natriuretic
peptide (CNP) for achondroplasia, continues to enroll on track. Dose-response
data from this study is expected in 2027.
• In October, five-year results from the PROPEL open-label extension study with
POMBILITI ® + OPFOLDA ® were presented in a late-breaking presentation at the
World Muscle Society Annual Congress. In adults with late-onset Pompe disease,
POMBILITI + OPFOLDA demonstrated durable motor function outcomes and relative
stabilization of pulmonary function. This included people who had received
enzyme replacement therapy for a mean of 7.6 years before enrolling. No new
safety signals were identified.
• For BMN 351, BioMarin’s Phase 1/2 candidate for Duchenne muscular dystrophy,
the company expects to provide a program update by year-end.
Growth
• In the first full quarter as part of BioMarin, GALAFOLD and POMBILITI +
OPFOLDA delivered strong quarterly revenue, contributing $152 million and $49
million, respectively. The number of patients treated with GALAFOLD and
POMBILITI + OPFOLDA increased by approximately 13% and 69% Y/Y, respectively.
POMBILITI + OPFOLDA uptake benefited from supply constraints for other Pompe
therapies.
• Metabolic Conditions revenue grew 44% Y/Y in the third quarter of 2026 and 26%
Y/Y year-to-date. Growth was driven by the additions of GALAFOLD and POMBILITI +
OPFOLDA and by higher VIMIZIM ® revenue. The number of patients on therapy
increased across all BioMarin-marketed Metabolic Conditions therapies, Y/Y.
• VOXZOGO revenue grew 12% Y/Y in the third quarter of 2026, and the number of
children treated with VOXZOGO globally increased 17% Y/Y. As of the end of the
quarter, children with achondroplasia in 58 countries around the world were
being treated with VOXZOGO. More than 75% of VOXZOGO revenue was generated
outside of the U.S., and a large international order previously expected in the
third quarter is now anticipated in the fourth quarter. In the U.S., the
majority of new patient starts were in children under the age of two.
2
Value Commitment
• BioMarin continued to integrate Amicus in the third quarter, realizing
accelerated cost synergies to enable investments in initiatives to drive future
growth of GALAFOLD and POMBILITI + OPFOLDA. BioMarin continues to expect
approximately $280 million of GAAP cost synergies (approximately $220 million on
a Non-GAAP basis) to be fully realized in 2028.
• On August 30, 2026, the company announced the global settlement of all
outstanding claims with Ascendis Pharma A/S related to its product Yuviwel. As
part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net
sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18%
of net sales in the European Union, Brazil and South Korea until May 2030.
Third Quarter 2026 Financial Highlights
•
Total Revenues
for the third quarter of 2026 were $1,025 million, an increase of 32% compared
to the same period in 2025, primarily driven by revenues from GALAFOLD and
POMBILITI + OPFOLDA, which were acquired on April 27, 2026, as well as 18%
revenue growth in VIMIZIM due to timing of large international orders. In the
quarter, VOXZOGO revenue also increased by 12% due to new patients initiating
therapy. These increases were partially offset by a decrease in NAGLAZYME ®
revenue due to timing of large international orders.
•
GAAP Net Loss
increased to $123 million compared to $31 million for the same period in 2025.
The increase was primarily driven by the acquisition of Amicus Therapeutics
(Amicus), including intangible asset amortization, interest expense from debt
issued to finance a portion of the transaction, amortization of inventory fair
value step-up, and integration and restructuring costs. The increase was also
attributed to acquired in-process research and development (IPR&D) charges
recorded in the quarter in connection with the acquisition of Alesta
Therapeutics (Alesta). These increases were partially offset by revenue growth
as described above.
•
Non-GAAP Income
for the third quarter of 2026 increased to $45 million compared to $22 million
for the same period in 2025. The increase was primarily driven by revenue
growth, partially offset by higher acquired IPR&D charges and higher interest
expense, as described above. The increases were also partially offset by higher
sales and marketing spend related to GALAFOLD and POMBILITI + OPFOLDA.
3
Financial Highlights (in millions of U.S. dollars, except percentages and per
share data, unaudited)
Three Nine
Months Months
Ended Ended
Septemb… Septemb…
30, 30,
2026 2025 % Change 2026 2025 % Change
Total $1,025 $776 32% $2,781 $2,347 18%
Revenu…
Net
Product
Revenu…
by
Produc…
VOXZOGO $245 $218 12% $717 $654 10%
Metabo…
Condit…
VIMIZIM $216 $183 18% $620 $587 6%
NAGLAZ… 108 122 (11)% 373 365 2%
PALYNZ… 111 109 2% 336 308 9%
GALAFO… 152 — NM 258 — NM
BRINEU… 53 48 10% 151 137 10%
ALDURA… 57 54 6% 137 159 (14)%
POMBIL…
+ 49 — NM 79 — NM
OPFOLDA
Total
Metabo… $744 $516 44% $1,954 $1,556 26%
Condit…
Revenue
KUVAN® $23 $24 (4)% $71 $76 (7)%
ROCTAV… $1 $3 (67)% $15 $23 (35)%
GAAP
Net $(123) $(31) 297% $27 $395 (93)%
Income
(Loss)
Non-GA… $45 $22 105% $430 $525 (18)%
Income…
GAAP
Operat… (8.0)% (6.0)% 5.7% 19.4%
Margin
%(3)
Non-GA…
Operat… 13.4% 2.8% 24.6% 26.3%
Margin
%(2)
GAAP
Diluted $(0.63) $(0.16) 294% $0.14 $2.04 (93)%
EPS
Non-GA…
Diluted $0.23 $0.12 92% $2.18 $2.69 (19)%
EPS(2)
NM Percentage change is not meaningful for products acquired from Amicus on
April 27, 2026.
(1) In 2026, the company announced that it will no longer market ROCTAVIAN.
(2) Refer to Non-GAAP Information beginning on page 10 of this press release for
definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non-
GAAP Diluted EPS along with the related reconciliations to the comparable
information reported under U.S. GAAP.
(3) GAAP Operating Margin percentage is defined by the company as GAAP Income
(Loss) from Operations divided by Total Revenues.
4
Forward-Looking Non-GAAP Financial Information
BioMarin does not provide guidance for GAAP reported financial measures (other
than revenue) or a reconciliation of forward-looking Non-GAAP financial measures
to the most directly comparable GAAP reported financial measures because the
company is unable to predict with reasonable certainty the financial impact of
changes resulting from its strategic portfolio and business operating model
reviews; potential future asset impairments; gains and losses on investments;
and other unusual gains and losses without unreasonable effort. These items are
uncertain, depend on various factors, and could have a material impact on GAAP
reported results for the guidance period. As such, any reconciliations provided
would imply a degree of precision that could be confusing or misleading to
investors.
Updated 2026 Full-Year Financial Guidance (in millions, except EPS amounts)
• Revenue: Total Revenues, Metabolic Conditions, and VOXZOGO guidance updated to
reflect uncertainty in the timing of multiple orders from a single international
customer.
• Non-GAAP Diluted EPS: BioMarin expects the Alesta acquisition and BMN 450
license agreement to result in total pre-tax charges of approximately $320
million and $83 million, respectively, for the full year 2026, consisting of the
acquired IPR&D charges and ongoing operating expenses, representing an
unfavorable impact of approximately $1.55 and $0.32, respectively, to both GAAP
Diluted EPS and Non-GAAP Diluted EPS for the full year 2026.
Provided
on Updated Midpoint
August November Growth
Item 6, 2026 2, 2026 (Y/Y)
──────────────────────────────────────────────────────────────────────────────
Total $3,875 to $3,925 $3,800 to $3,900 20%
Revenu…
Metabo… $2,725 to $2,775 $2,675 to $2,750 29%
Condit…
VOXZOGO $1,000 to $1,050 $975 to $1,025 8%
Other $100 to $125 $125 to $150
Revenu…
Non-GA…
Diluted $4.90 to $5.10 $2.80 to $3.10 (6)%
EPS(2)…
(1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties.
(2) Refer to Non-GAAP Information beginning on page 10 of this press release for
definition of Non-GAAP Diluted EPS.
(3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-
Average Diluted Shares Outstanding.
BioMarin will host a conference call and webcast to discuss third quarter 2026
financial results today, Monday, November 2, 2026, at 4:30 p.m. ET. This event
can be accessed through this link or on the investor section of the BioMarin
website at www.biomarin.com.
U.S./Canada Dial-in Number:+1 Replay Dial-in Number: +1 833-309-1852
833-461-5787
International Dial-in Number: +1 Replay International Dial-in Number: +44
626-884-3620 800 007 4044
Conference ID: 324 588 583 Conference ID: 324 588 583
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on
delivering medicines for people living with genetically defined conditions.
Founded in 1997, the San Rafael, California-based company has a proven track
record of innovation, with nine commercial therapies and a strong clinical and
preclinical pipeline. Using a distinctive approach to drug discovery and
development, BioMarin seeks to unleash the full potential of genetic science by
pursuing category-defining medicines that have a profound impact on patients. To
learn more, please visit www.biomarin.com.
5
Forward-Looking Statements
This press release and the associated conference call and webcast contain
forward-looking statements about the business prospects of BioMarin
Pharmaceutical Inc. (BioMarin), including, without limitation, statements about:
future financial performance, including the expectations of Revenues and Non-
GAAP Diluted EPS for, in certain instances, the full-year 2026 and fourth
quarter of 2026, and future periods, and the underlying drivers of those
results, such as the expected demand and continued growth of BioMarin’s
Metabolic Conditions portfolio, including PALYNZIQ, GALAFOLD and POMBILITI +
OPFOLDA, and VOXZOGO, and the expected impact of the acquisition of Alesta
Therapeutics B.V. (Alesta) and the BMN 450 license agreement; the anticipated
benefits of the acquisition of Amicus Therapeutics, Inc., including the expected
amount and timing of cost synergies as well as expected revenue from the
addition of GALAFOLD and POMBILITI + OPFOLDA; the anticipated benefits of the
acquisition of Alesta; the anticipated benefits of the BMN 450 license
agreement; the anticipated benefits of the global settlement with Ascendis
Pharma A/S, including BioMarin’s expected receipt of royalty payments on net
sales of Yuviwel in the United States, the European Union, Brazil and South
Korea; BioMarin’s plans for investment in innovation and future growth; the
timing of orders for commercial products; plans and expectations regarding the
development, commercialization and commercial prospects of BioMarin’s product
candidates and commercial products, including the prospects and timing of
actions relating to clinical studies and trials and product approvals, such as
study initiations, study advancements, data readouts, submissions, filings,
approvals, and label expansions; the expected benefits and availability of
BioMarin’s commercial products and product candidates, including with respect to
the potential new indication for VOXZOGO in hypochondroplasia; and potential
growth opportunities and trends, including the assumptions and expectations
regarding total addressable patient population (TAPP) with respect to the
conditions targeted by BioMarin’s product candidates and commercial products.
These forward-looking statements are predictions and involve risks and
uncertainties such that actual results may differ materially from these
statements. These risks and uncertainties include, among others: BioMarin’s
success in the commercialization of its commercial products; BioMarin’s ability
to successfully integrate and realize the anticipated benefits of any
acquisitions and license agreements; BioMarin’s ability to accurately estimate
future financial performance; impacts of macroeconomic and other external
factors on BioMarin’s operations, regulatory uncertainty, the impact of new or
increased tariffs, other trade protection measures, and escalating trade
tensions; geopolitical instability, wars and military conflicts; results and
timing of current and planned preclinical studies and clinical trials and the
release of data from those trials; BioMarin’s ability to successfully
manufacture its commercial products and product candidates; the content and
timing of decisions by the U.S. Food and Drug Administration, the European
Medicines Agency, the European Commission and other regulatory authorities
concerning each of the described products and product candidates; the market for
each of these products; BioMarin’s ability to meet product demand; actual sales
of BioMarin’s commercial products; and those factors detailed in BioMarin's
filings with the Securities and Exchange Commission, including, without
limitation, the factors contained under the caption “Risk Factors” in BioMarin's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such
factors may be updated by any subsequent reports. Investors are urged not to
place undue reliance on forward-looking statements, which speak only as of the
date hereof. BioMarin is under no obligation, and expressly disclaims any
obligation to update or alter any forward-looking statement, whether as a result
of new information, future events or otherwise.
BioMarin ® , VOXZOGO ® , VIMIZIM ® , NAGLAZYME ® , PALYNZIQ ® , BRINEURA ® ,
KUVAN ® , ROCTAVIAN ® , GALAFOLD ® , and POMBILITI ® + OPFOLDA ® are registered
trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME ® is a
registered trademark of BioMarin/Genzyme LLC. All other brand names and service
marks, trademarks and other trade names appearing in this release are the
property of their respective owners.
6
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Three and Nine Months Ended September 30, 2026 and 2025
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
REVE… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
prod… $ 1,013… $ 760,812 $ 2,757,… $ 2,308…
reve…
Roya…
and 11,566 15,321 23,011 38,250
other
reve…
Total 1,024… 776,133 2,780,… 2,346…
reve…
OPER…
EXPE…
Cost
of 205,4… 140,085 603,210 441,7…
sales
Rese…
and 180,5… 188,515 566,273 508,5…
deve…
Acqu…
in-p…
rese… 287,6… 220,963 287,685 220,9…
and
deve…
(IPR…
Sell…
gene… 333,6… 268,415 987,482 706,8…
and
admi…
Inta…
asset 99,458 4,847 177,433 14,540
amor…
Total
oper… 1,106… 822,825 2,622,… 1,892…
expe…
INCO…
(LOS… -82,0… -46,692 158,479 454,0…
FROM
OPER…
Inte… 4,630 17,854 37,670 55,694
inco…
Inte… -55,6… -2,579 -133,8… -8,121
expe…
Other
inco… 1,310 5,093 8,550 7,972
net
INCO…
(LOS…
BEFO… -131,… -26,324 70,818 509,6…
INCO…
TAXES
Prov…
for
(ben… -8,938 4,420 43,360 114,1…
from)
inco…
taxes
NET
INCO… $ -122,… $ -30,744 $ 27,458 $ 395,4…
(LOS…
EARN…
(LOS…
PER $ -0.63 $ -0.16 $ 0.14 $ 2.06
SHAR…
BASIC
EARN…
(LOS…
PER $ -0.63 $ -0.16 $ 0.14 $ 2.04
SHAR…
DILU…
Weig…
aver…
comm… 193,5… 192,032 193,171 191,6…
shar…
outs…
basic
Weig…
aver…
comm… 193,5… 192,032 195,214 196,8…
shar…
outs…
dilu…
7
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30, 2026 and December 31, 2025
(In thousands of U.S. dollars, except per share amounts)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-Unaudited
ASSETS
Current
assets:
Cash and cash $ 736,007 $ 1,311,679
equivalents
Short-term — 248,930
investments
Accounts
receivable, 1,076,355 908,214
net
Inventory 1,796,069 1,298,883
Other current 312,205 185,784
assets
Total current 3,920,636 3,953,490
assets
Noncurrent
assets:
Long-term — 492,242
investments
Property,
plant and 980,081 952,508
equipment, net
Intangible 4,777,247 213,837
assets, net
Goodwill 666,367 196,199
Deferred tax 897,787 1,508,697
assets
Other assets 327,113 277,049
Total assets $ 11,569,231 $ 7,594,022
LIABILITIES
AND
STOCKHOLDERS’
EQUITY
Current
liabilities:
Accounts
payable and $ 946,107 $ 759,031
accrued
liabilities
Current
portion of 658,717 —
long-term
debt, net
Total current 1,604,824 759,031
liabilities
Noncurrent
liabilities:
Long-term 3,514,974 597,176
debt, net
Other
long-term 193,401 150,816
liabilities
Total 5,313,199 1,507,023
liabilities
Stockholders’
equity:
Common stock,
$0.001 par
value:
500,000,000
shares
authorized;
193,676,831 194 192
and
192,300,101
shares
issued and
outstanding,
respectively
Additional
paid-in 6,089,036 5,956,582
capital
Company common
stock held by
the
Nonqualified -10,851 -10,508
Deferred
Compensation
Plan
Accumulated
other -4,011 -13,473
comprehensive
loss
Retained 181,664 154,206
earnings
Total
stockholders’ 6,256,032 6,086,999
equity
Total
liabilities
and $ 11,569,231 $ 7,594,022
stockholders’
equity
8
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30, 2026 and 2025
(In thousands of U.S. dollars)
(Unaudited)
CASH FLOWS FROM Nine Months Ended
OPERATING September 30,
ACTIVITIES: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 27,458 $ 395,474
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 244,514 59,119
amortization
Non-cash interest 30,548 1,969
expense
Stock-based 172,684 134,496
compensation
Impairment of assets 15,203 2,967
Acquired IPR&D 282,258 220,963
expense
Deferred income -27,490 48,125
taxes
Unrealized foreign
exchange losses -8,380 244
(gains)
Other -7,091 -5,399
Changes in operating
assets and
liabilities, net of
effects of business
acquired:
Accounts receivable, -60,435 -107,378
net
Inventory -1,621 -98,796
Other current assets -54,369 -32,125
Other assets 12,859 -32,679
Accounts payable and -52,675 119,478
accrued liabilities
Other long-term 3,511 21,892
liabilities
Net cash provided by
operating 576,974 728,350
activities
CASH FLOWS FROM
INVESTING
ACTIVITIES:
Purchases of
property, plant and -78,032 -62,316
equipment
Maturities and sales 767,277 294,547
of investments
Purchases of -25,792 -313,262
investments
Business
combination, net of -5,067,630 —
cash
acquired
Purchases of IPR&D, -277,881 -285,193
net of cash acquired
Other investing -1,191 -5,569
activities, net
Net cash used in -4,683,249 -371,793
investing activities
CASH FLOWS FROM
FINANCING
ACTIVITIES:
Proceeds from
exercises of awards
under 6,655 7,714
equity incentive
plans
Taxes paid related
to net share -43,330 -53,265
settlement of equity
awards
Proceeds from 3,650,000 —
borrowings
Payments of debt -65,605 —
issuance costs
Repayments of -15,000 —
borrowings
Net cash provided by
(used in) financing 3,532,720 -45,551
activities
Effect of exchange -2,117 -3,740
rate changes on cash
NET INCREASE
(DECREASE) IN CASH -575,672 307,266
AND CASH
EQUIVALENTS
Cash and cash
equivalents:
Beginning of period $ 1,311,679 $ 942,842
End of period $ 736,007 $ 1,250,108
9
Non-GAAP Information
The results presented in this press release include both GAAP information and
Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net
Income (Loss) excluding amortization, stock-based compensation expense and, in
certain periods, certain other specified items, as detailed below when
applicable. The company also includes a Non-GAAP adjustment for the estimated
tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D
expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are
defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses,
respectively, excluding stock-based compensation expense and, in certain
periods, certain other specified items, as detailed below when applicable. Non-
GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss)
from Operations, excluding amortization of intangible assets, stock-based
compensation expense and, in certain periods, certain other specified items,
divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company
as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares
Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by
the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to
include any common shares issuable under the company’s equity plans or
convertible debt in periods when they are dilutive under Non-GAAP. Non-GAAP
synergies is defined by the company as Amicus’ legacy labor and external spend
cost reductions, excluding the impact of stock-based compensation.
BioMarin regularly uses both GAAP and Non-GAAP results and expectations
internally to assess its financial operating performance and evaluate key
business decisions related to its principal business activities: the discovery,
development, manufacture, marketing and sale of innovative biologic therapies.
BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate
its business and to make operating decisions, and compensation of executives is
based in part on this measure. Because these Non-GAAP metrics are important
internal measurements for BioMarin, the company believes that providing this
information in conjunction with BioMarin’s GAAP information enhances investors’
and analysts’ ability to meaningfully compare the company’s results from period
to period and to its forward-looking guidance, and to identify operating trends
in the company’s principal business.
Non-GAAP financial measures are not meant to be considered in isolation or as a
substitute for, or superior to comparable GAAP measures and should be read in
conjunction with the consolidated financial information prepared in accordance
with GAAP. Investors should note that the Non-GAAP information is not prepared
under any comprehensive set of accounting rules or principles and does not
reflect all of the amounts associated with the company’s results of operations
as determined in accordance with GAAP. Investors should also note that these
Non-GAAP financial measures have no standardized meaning prescribed by GAAP and,
therefore, have limits in their usefulness to investors. In addition, from time
to time in the future there may be other items that the company may exclude for
purposes of its Non-GAAP financial measures; likewise, the company may in the
future cease to exclude items that it has historically excluded for purposes of
its Non-GAAP financial measures. Because of the non-standardized definitions,
the Non-GAAP financial measure as used by BioMarin in this press release and the
accompanying tables may be calculated differently from, and therefore may not be
directly comparable to, similarly titled measures used by other companies.
The following tables present the reconciliation of GAAP reported to Non-GAAP
adjusted financial information:
10
Reconciliation of GAAP Reported Information to Non-GAAP Information (1)
(In millions, except percentages and per share data)
(unaudited)
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Reported
Net $ -123 $ -31 $ 27 $ 395
Income
(Loss)
Adjustme…
Stock-ba…
compensa… 4 4 13 11
expense -
COS
Stock-ba…
compensa… 14 15 41 41
expense -
R&D
Stock-ba…
compensa… 36 30 119 83
expense -
SG&A(2)
Amortiza…
of 99 5 177 15
intangib…
assets
Amortiza…
of
acquired 18 — 29 —
inventory
step-up -
COS(3)
Acquisit…
and
restruct… 47 15 143 15
costs -
SG&A(4)
Loss on — — — 3
investme…
Income
tax -50 -16 -120 -38
effect of
adjustme…
Non-GAAP $ 45 $ 22 $ 430 $ 525
Income
Thr…
Mon…
End…
Sep…
30,
2026 2025
COS R&D SG… COS R&D SG…
──────────────────────────────────────────────────────────────────────────────
G… $ 205 $ 181 $ 334 $ 140 $ 189 $ 268
e…
A…
S…
c… -4 -14 -36 -4 -15 -30
e…
A…
of
a… -18 — — — — —
i…
s…
A…
a… — — -47 — — -15
r…
c…
N… $ 184 $ 167 $ 249 $ 136 $ 174 $ 223
e…
Ni…
Mo…
En…
Se…
30,
20… 2025
COS R&D SG&A COS R&D SG…
──────────────────────────────────────────────────────────────────────────────
G… $ 603 $ 566 $ 987 $ 442 $ 509 $ 707
e…
A…
S…
c… -13 -41 -1… -11 -41 -83
e…
A…
of
a… -29 — — — — —
i…
s…
A…
a… — — -1… — — -15
r…
c…
N… $ 561 $ 525 $ 724 $ 431 $ 468 $ 609
e…
11
… … … … … …
… … … … … …
… … … … … …
… … … … … …
… … … … … … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … … % $ … … % $ … … % $ … … %
… … … … … … … …
… … 5 … … … … …
… … — — … … — —
… … … … … … … …
$ … … % $ … … % $ … … % $ … … %
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Diluted $ -0.63 $ -0.16 $ 0.14 $ 2.04
EPS
Adjustm…
Stock-b…
compens… $ 0.28 $ 0.25 0.87 0.69
expense…
Amortiz…
of $ 0.51 $ 0.03 0.89 0.08
intangi…
assets
Amortiz…
of
acquired $ 0.09 $ — 0.15 —
invento…
step-up…
Acquisi…
and $ 0.24 $ 0.08 0.72 0.08
restruc…
costs(4)
Loss on $ — $ — — 0.02
investm…
Income
tax
effect $ -0.26 $ -0.08 -0.60 -0.19
of
adjustm…
Non-GAAP
Diluted $ 0.23 $ 0.12 $ 2.18 $ 2.69
EPS
Three Nine
Mont… Months
Ended Ended
Sept… Septe…
30, 30,
2026 2025 2026 2025
GAAP
Weig…
Dilu… 193.6 192.0 195.2 196.9
Shar…
Outs…
Adju…
Comm…
stock
issu…
under 2.5 0.8 — —
the
comp…
equi…
plans
Comm…
stock
issu…
under — — 4.4 —
the
comp…
conv…
debt
Non-…
Weig…
Dilu… 196.0 192.8 199.6 196.9
Shar…
Outs…
(1) Certain amounts may not sum or recalculate due to rounding.
(2) Stock-based compensation expense recorded in SG&A for the nine months ended
September 30, 2026, includes approximately $13 million related to the post-
combination service period for unvested Amicus stock options.
(3) Represents amortization of the inventory step-up for the inventory acquired
in the Amicus transaction.
(4) The 2026 amounts represent severance, transaction and integration costs
resulting from the Amicus acquisition, as well as restructuring costs incurred
in connection with corporate initiatives. The 2025 amounts represent severance
costs incurred in connection with the acquisition of Inozyme Pharma, Inc.
(5) Represents impairment loss on non-marketable equity securities recorded in
Other income, net, in the first quarter of 2025.
(6) Common stock issuable under the company’s equity plans and convertible debt
were excluded from the computation of GAAP and Non-GAAP Weighted-Average Diluted
Shares Outstanding in the periods they were anti-dilutive.
12